Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New study tests immune combo before brain surgery in melanoma patients

NCT ID NCT05704933

First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 20 times

Summary

This early-phase study tested whether giving a single dose of nivolumab with either ipilimumab or relatlimab before brain surgery is safe and feasible in adults with melanoma that has spread to the brain. Only one person enrolled, so the main goal was to see if recruitment was possible. Researchers also looked at immune cell changes in the tumor and blood samples.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • M.D. Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Moffitt Cancer Center

    Tampa, Florida, 33612, United States

Conditions

Explore the condition pages connected to this study.